Assetmark Inc. Raises Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Assetmark Inc. raised its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 9.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,033 shares of the biopharmaceutical company’s stock after purchasing an additional 847 shares during the period. Assetmark Inc.’s holdings in Alnylam Pharmaceuticals were worth $2,361,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in ALNY. Jennison Associates LLC purchased a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at approximately $61,160,000. Proficio Capital Partners LLC raised its position in Alnylam Pharmaceuticals by 25,929.6% during the fourth quarter. Proficio Capital Partners LLC now owns 193,660 shares of the biopharmaceutical company’s stock valued at $45,570,000 after purchasing an additional 192,916 shares during the period. Strategic Financial Concepts LLC purchased a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at approximately $41,529,000. Eventide Asset Management LLC raised its position in Alnylam Pharmaceuticals by 157.9% during the third quarter. Eventide Asset Management LLC now owns 224,333 shares of the biopharmaceutical company’s stock valued at $61,698,000 after purchasing an additional 137,333 shares during the period. Finally, Los Angeles Capital Management LLC raised its position in Alnylam Pharmaceuticals by 11,433.4% during the third quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock valued at $37,684,000 after purchasing an additional 135,829 shares during the period. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ALNY. Scotiabank cut their target price on Alnylam Pharmaceuticals from $310.00 to $300.00 and set a “sector outperform” rating on the stock in a research note on Friday, February 14th. William Blair reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 26th. Needham & Company LLC reaffirmed a “buy” rating and set a $320.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 26th. Piper Sandler reaffirmed an “overweight” rating and set a $296.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. Finally, Wolfe Research cut Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research note on Tuesday, November 12th. One analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $304.26.

Alnylam Pharmaceuticals Stock Down 1.5 %

Shares of NASDAQ ALNY opened at $244.52 on Monday. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The stock has a market capitalization of $31.65 billion, a PE ratio of -112.68 and a beta of 0.39. The stock’s fifty day simple moving average is $254.70 and its two-hundred day simple moving average is $261.25. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insider Activity

In other news, CMO Pushkal Garg sold 1,752 shares of the stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $251.00, for a total transaction of $439,752.00. Following the completion of the sale, the chief marketing officer now owns 15,705 shares in the company, valued at approximately $3,941,955. This represents a 10.04 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of the stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.21, for a total value of $169,204.23. Following the sale, the executive vice president now owns 14,321 shares of the company’s stock, valued at approximately $3,654,862.41. This represents a 4.42 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 72,986 shares of company stock worth $20,397,849. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.